| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
|
Arthritis Rheum
|
2012
|
6.85
|
|
2
|
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
|
Arthritis Rheum
|
2010
|
4.57
|
|
3
|
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study.
|
Arthritis Rheum
|
2013
|
4.02
|
|
4
|
Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin.
|
Arthritis Res Ther
|
2005
|
3.17
|
|
5
|
Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis.
|
J Rheumatol
|
2005
|
2.28
|
|
6
|
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.
|
Ann Rheum Dis
|
2012
|
2.21
|
|
7
|
Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus.
|
Arthritis Rheum
|
2007
|
1.98
|
|
8
|
Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices.
|
Best Pract Res Clin Rheumatol
|
2005
|
1.94
|
|
9
|
Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program.
|
Arthritis Rheumatol
|
2014
|
1.91
|
|
10
|
Numerical scoring for the BILAG-2004 index.
|
Rheumatology (Oxford)
|
2010
|
1.83
|
|
11
|
The incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia Lupus Registry.
|
Arthritis Rheumatol
|
2014
|
1.83
|
|
12
|
Anti-inflammatory and immunosuppressive drugs and reproduction.
|
Arthritis Res Ther
|
2006
|
1.78
|
|
13
|
British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus.
|
Arthritis Rheum
|
2007
|
1.74
|
|
14
|
Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study.
|
J Rheumatol
|
2009
|
1.67
|
|
15
|
Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus.
|
Rheumatology (Oxford)
|
2009
|
1.65
|
|
16
|
Ocular manifestations of systemic lupus erythematosus.
|
Rheumatology (Oxford)
|
2007
|
1.64
|
|
17
|
Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006.
|
Rheumatology (Oxford)
|
2013
|
1.58
|
|
18
|
Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity.
|
Arthritis Rheum
|
2006
|
1.56
|
|
19
|
The BILAG-2004 index is sensitive to change for assessment of SLE disease activity.
|
Rheumatology (Oxford)
|
2009
|
1.52
|
|
20
|
Cancer risk in systemic lupus: an updated international multi-centre cohort study.
|
J Autoimmun
|
2013
|
1.47
|
|
21
|
Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS).
|
Rheumatology (Oxford)
|
2013
|
1.46
|
|
22
|
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.
|
Ann Rheum Dis
|
2014
|
1.45
|
|
23
|
Mycophenolate mofetil for remission induction in severe lupus nephritis.
|
Nephron Clin Pract
|
2005
|
1.44
|
|
24
|
Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
|
Rheumatology (Oxford)
|
2009
|
1.41
|
|
25
|
Usefulness of the British Isles Lupus Assessment Group index in pediatric clinical trials: comment on the article by Ruperto et al.
|
Arthritis Rheum
|
2006
|
1.39
|
|
26
|
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.
|
Ann Rheum Dis
|
2013
|
1.25
|
|
27
|
The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients.
|
Rheumatology (Oxford)
|
2011
|
1.25
|
|
28
|
Synovial fluid leukocyte apoptosis is inhibited in patients with very early rheumatoid arthritis.
|
Arthritis Res Ther
|
2006
|
1.16
|
|
29
|
Numerical scoring for the Classic BILAG index.
|
Rheumatology (Oxford)
|
2009
|
1.13
|
|
30
|
Primary anti-phospholipid antibody syndrome (APS): current concepts.
|
Surv Ophthalmol
|
2002
|
1.13
|
|
31
|
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up.
|
Rheumatology (Oxford)
|
2013
|
1.10
|
|
32
|
Population-based lupus registries: advancing our epidemiologic understanding.
|
Arthritis Rheum
|
2009
|
1.10
|
|
33
|
Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study.
|
Arthritis Rheum
|
2006
|
1.09
|
|
34
|
Managing lupus nephritis in pregnant women: comment on the article by Hahn et al.
|
Arthritis Care Res (Hoboken)
|
2013
|
1.08
|
|
35
|
Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group.
|
J Rheumatol
|
2004
|
1.07
|
|
36
|
Tumor necrosis factor alpha activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint.
|
Arthritis Rheum
|
2007
|
1.04
|
|
37
|
Lymphoma risk in systemic lupus: effects of disease activity versus treatment.
|
Ann Rheum Dis
|
2013
|
1.03
|
|
38
|
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.
|
Ann Rheum Dis
|
2012
|
1.02
|
|
39
|
Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.
|
Arthritis Rheum
|
2010
|
0.94
|
|
40
|
In utero azathioprine exposure and increased utilization of special educational services in children born to mothers with systemic lupus erythematosus.
|
Arthritis Care Res (Hoboken)
|
2013
|
0.94
|
|
41
|
Systemic lupus and malignancies.
|
Curr Opin Rheumatol
|
2012
|
0.94
|
|
42
|
Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index.
|
Arthritis Rheum
|
2008
|
0.94
|
|
43
|
Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response.
|
Arthritis Rheum
|
2008
|
0.94
|
|
44
|
The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs.
|
Arthritis Rheum
|
2007
|
0.92
|
|
45
|
Systemic lupus erythematosus: clinical presentations.
|
Autoimmun Rev
|
2010
|
0.92
|
|
46
|
Clinical trials in lupus: what have we learned so far?
|
Rheumatology (Oxford)
|
2010
|
0.89
|
|
47
|
Anti-TNF therapy and pregnancy outcomes in women with inflammatory arthritis.
|
Expert Rev Clin Immunol
|
2009
|
0.87
|
|
48
|
Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study.
|
Ann Rheum Dis
|
2012
|
0.86
|
|
49
|
Managing pregnancy in inflammatory rheumatological diseases.
|
Arthritis Res Ther
|
2011
|
0.86
|
|
50
|
Assessment of disease activity and quality of life in systemic lupus erythematosus - New aspects.
|
Best Pract Res Clin Rheumatol
|
2009
|
0.86
|
|
51
|
New biologic therapy for systemic lupus erythematosus.
|
Curr Opin Pharmacol
|
2013
|
0.85
|
|
52
|
Family planning and pregnancy issues for women with systemic inflammatory diseases: patient and physician perspectives.
|
BMJ Open
|
2014
|
0.84
|
|
53
|
The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE.
|
Rheumatology (Oxford)
|
2010
|
0.83
|
|
54
|
The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patients.
|
Rheumatology (Oxford)
|
2012
|
0.83
|
|
55
|
Novel treatments for systemic lupus erythematosus.
|
Curr Opin Investig Drugs
|
2010
|
0.83
|
|
56
|
25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort.
|
Arthritis Care Res (Hoboken)
|
2014
|
0.83
|
|
57
|
The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus.
|
J Rheumatol
|
2010
|
0.83
|
|
58
|
Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort.
|
Arthritis Care Res (Hoboken)
|
2015
|
0.82
|
|
59
|
The Aspergillus fumigatus cellobiohydrolase B (cbhB) promoter is tightly regulated and can be exploited for controlled protein expression and RNAi.
|
FEMS Microbiol Lett
|
2006
|
0.82
|
|
60
|
Pregnancy and reproduction in autoimmune rheumatic diseases.
|
Rheumatology (Oxford)
|
2010
|
0.82
|
|
61
|
Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people, 2007-2009.
|
Arthritis Rheumatol
|
2014
|
0.81
|
|
62
|
Causes and management of infertility in systemic lupus erythematosus.
|
Rheumatology (Oxford)
|
2011
|
0.81
|
|
63
|
Biologic therapy and pregnancy outcomes in women with rheumatic diseases.
|
Arthritis Rheum
|
2009
|
0.81
|
|
64
|
A nonsense mutation in exon 2 of the DNase I gene is not present in UK subjects with systemic lupus erythematosus and Graves' disease: Comment on the article by Rood et al.
|
Arthritis Rheum
|
2002
|
0.80
|
|
65
|
B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
|
BioDrugs
|
2013
|
0.80
|
|
66
|
Candidate T cell epitopes of the human La/SSB autoantigen.
|
Arthritis Rheum
|
2002
|
0.80
|
|
67
|
The BILAG-2004 systems tally--a novel way of representing the BILAG-2004 index scores longitudinally.
|
Rheumatology (Oxford)
|
2012
|
0.80
|
|
68
|
Challenges of ethnicity in SLE.
|
Best Pract Res Clin Rheumatol
|
2009
|
0.80
|
|
69
|
Decreased live births in women with systemic lupus erythematosus.
|
Arthritis Care Res (Hoboken)
|
2011
|
0.80
|
|
70
|
American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort.
|
J Rheumatol
|
2014
|
0.79
|
|
71
|
Systemic lupus erythematosus in women: impact on family size.
|
Arthritis Rheum
|
2008
|
0.79
|
|
72
|
Advances in the assessment of lupus disease activity and damage.
|
Curr Opin Rheumatol
|
2014
|
0.79
|
|
73
|
Incidence and prevalence of systemic lupus erythematosus among Arab and Chaldean Americans in southeastern Michigan: the Michigan Lupus Epidemiology and Surveillance Program.
|
Am J Public Health
|
2015
|
0.77
|
|
74
|
Refractory multisystem sarcoidosis responding to infliximab therapy.
|
Clin Rheumatol
|
2012
|
0.77
|
|
75
|
Experience with a Punjabi, Urdu and Hindi rheumatology telephone helpline.
|
Musculoskeletal Care
|
2009
|
0.76
|
|
76
|
GPs have key role in shared care of patients with SLE.
|
Practitioner
|
2009
|
0.76
|
|
77
|
Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis.
|
BMJ Open
|
2013
|
0.76
|
|
78
|
Contemporary treatment of systemic lupus erythematosus: an update for clinicians.
|
Ther Adv Chronic Dis
|
2010
|
0.76
|
|
79
|
Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus.
|
Ann Rheum Dis
|
2007
|
0.75
|
|
80
|
Sequential therapies for proliferative lupus nephritis.
|
N Engl J Med
|
2004
|
0.75
|
|
81
|
Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus.
|
Immunotherapy
|
2014
|
0.75
|
|
82
|
The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus.
|
Clin Rheumatol
|
2015
|
0.75
|
|
83
|
Lupus and zoster.
|
Lancet
|
2003
|
0.75
|